Please check your internet connection and try again.
# Piperacillin/Tazobactam
## Overview
Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a penicillinase-sensitive extended-spectrum penicillin, and tazobactam, a beta-lactamase inhibitor. This combination broadens the spectrum of activity against many beta-lactamase producing bacteria. It is typically administered intravenously.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections (including diabetic foot infections)
* Community-acquired pneumonia
* Nosocomial pneumonia
* Nosocomial intra-abdominal infections
* Febrile neutropenia (as part of combination therapy)
## Adult Dosing
The typical adult dose is 3.375 grams (3 grams piperacillin/0.375 grams tazobactam) or 4.5 grams (4 grams piperacillin/0.5 grams tazobactam) administered every 6 or 8 hours. Dosing frequency and duration depend on the severity and type of infection, as well as clinical response. For severe infections, especially nosocomial pneumonia or febrile neutropenia, continuous infusion may be considered, which might necessitate a higher total daily dose. Specific dosing and infusion strategies for severe infections should follow institutional guidelines.
## Pediatric Dosing
Dosing in pediatric patients is based on the piperacillin component.
* **Patients 1 month to 12 years:** Doses range from 50 mg/kg to 100 mg/kg of piperacillin every 6 or 8 hours. The corresponding tazobactam dose is 6.25 mg/kg to 12.5 mg/kg.
* **Patients 12 years and older:** Dosing is typically the same as adults (3.375g or 4.5g every 6 or 8 hours).
* **Neonates and infants younger than 1 month:** Dosing is typically 50 mg/kg piperacillin every 12 hours for premature infants and every 8 hours for term infants.
Maximum doses should not exceed adult recommendations. All pediatric dosing should be guided by institutional protocols and weight-based calculations.
## Dose Adjustments
* **Renal Impairment:** Dose reduction and/or increased dosing interval is necessary in patients with significant renal impairment (CrCl < 40 mL/min).
* CrCl 20-40 mL/min: Administer usual dose every 8 hours.
* CrCl < 20 mL/min: Administer usual dose every 12 hours.
* Hemodialysis: Administer usual dose every 12 hours and supplement with an additional dose after each dialysis session.
* *Note: Dosing adjustments for continuous infusions in renal impairment are complex and should follow specific protocols.*
## Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillinase-resistant synthetic penicillins, or any component of the formulation.
* History of severe allergic reaction (e.g., anaphylaxis) to a beta-lactam antibiotic.
## Adverse Effects
Common adverse effects include diarrhea, nausea, vomiting, rash, insomnia, headache, and abdominal pain. More serious adverse effects include Clostridioides difficile-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, neutropenia, thrombocytopenia, and elevated liver enzymes.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin/tazobactam plasma concentrations.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the anticoagulant effect of warfarin. Monitor INR closely.
* **Methotrexate:** Penicillins may reduce the renal clearance of methotrexate, leading to increased toxicity. Monitor methotrexate levels.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for signs and symptoms of Clostridioides difficile infection.
* Monitor renal function, especially in patients with pre-existing renal impairment or those receiving nephrotoxic agents.
* Monitor complete blood counts, particularly in patients receiving prolonged therapy.
* Monitor liver function tests.
* Monitor INR if the patient is also taking warfarin.
## Clinical Pearls
* Piperacillin/tazobactam has a broad spectrum of activity including many gram-positive, gram-negative (including *Pseudomonas aeruginosa*), and anaerobic organisms.
* It is often used for empirical treatment of serious infections, especially in hospital-acquired settings.
* Consider the possibility of cross-reactivity in patients with penicillin allergies.
* Ensure adequate hydration to minimize the risk of crystalluria.
* Reconstituted solutions have limited stability and should be used promptly or refrigerated as per manufacturer guidelines.
***
*Disclaimer: This information is intended for clinical pharmacists and healthcare professionals. It is crucial to consult the most current prescribing information (e.g., FDA-approved labeling) and institutional guidelines for complete and up-to-date recommendations before prescribing or administering any medication.*
